A citation-based method for searching scientific literature

C W Szeto, R Kurzrock, S Kato, A Goloubev, S Veerapaneni, A Preble, S K Reddy, J J Adashek. ESMO Open 2022
Times Cited: 3







List of co-cited articles
12 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Molecular profiling of cancer patients enables personalized combination therapy: the I-PREDICT study.
Jason K Sicklick, Shumei Kato, Ryosuke Okamura, Maria Schwaederle, Michael E Hahn, Casey B Williams, Pradip De, Amy Krie, David E Piccioni, Vincent A Miller,[...]. Nat Med 2019
267
100

Real-world data from a molecular tumor board demonstrates improved outcomes with a precision N-of-One strategy.
Shumei Kato, Ki Hwan Kim, Hyo Jeong Lim, Amelie Boichard, Mina Nikanjam, Elizabeth Weihe, Dennis J Kuo, Ramez N Eskander, Aaron Goodman, Natalie Galanina,[...]. Nat Commun 2020
92
100

Missing the target in cancer therapy.
Jacob J Adashek, Alexey Goloubev, Shumei Kato, Razelle Kurzrock. Nat Cancer 2021
5
100

Genomic and transcriptomic profiling expands precision cancer medicine: the WINTHER trial.
Jordi Rodon, Jean-Charles Soria, Raanan Berger, Wilson H Miller, Eitan Rubin, Aleksandra Kugel, Apostolia Tsimberidou, Pierre Saintigny, Aliza Ackerstein, Irene Braña,[...]. Nat Med 2019
217
66

Targeting G1/S phase cell-cycle genomic alterations and accompanying co-alterations with individualized CDK4/6 inhibitor-based regimens.
Shumei Kato, Ryosuke Okamura, Jacob J Adashek, Noor Khalid, Suzanna Lee, Van Nguyen, Jason K Sicklick, Razelle Kurzrock. JCI Insight 2021
12
66

From Tissue-Agnostic to N-of-One Therapies: (R)Evolution of the Precision Paradigm.
Jacob J Adashek, Vivek Subbiah, Razelle Kurzrock. Trends Cancer 2021
34
66

Signed in Blood: Circulating Tumor DNA in Cancer Diagnosis, Treatment and Screening.
Jacob J Adashek, Filip Janku, Razelle Kurzrock. Cancers (Basel) 2021
15
66

Concomitant MEK and Cyclin Gene Alterations: Implications for Response to Targeted Therapeutics.
Shumei Kato, Jacob J Adashek, Justin Shaya, Ryosuke Okamura, Rebecca E Jimenez, Suzanna Lee, Jason K Sicklick, Razelle Kurzrock. Clin Cancer Res 2021
11
66

Hyperprogressors after Immunotherapy: Analysis of Genomic Alterations Associated with Accelerated Growth Rate.
Shumei Kato, Aaron Goodman, Vighnesh Walavalkar, Donald A Barkauskas, Andrew Sharabi, Razelle Kurzrock. Clin Cancer Res 2017
557
66

Hyperprogression and Immunotherapy: Fact, Fiction, or Alternative Fact?
Jacob J Adashek, Ishwaria M Subbiah, Ignacio Matos, Elena Garralda, Arjun K Menta, Dhakshina Moorthy Ganeshan, Vivek Subbiah. Trends Cancer 2020
53
66

Transcriptomic silencing as a potential mechanism of treatment resistance.
Jacob J Adashek, Shumei Kato, Rahul Parulkar, Christopher W Szeto, J Zachary Sanborn, Charles J Vaske, Stephen C Benz, Sandeep K Reddy, Razelle Kurzrock. JCI Insight 2020
18
66

Molecular profiling of advanced malignancies guides first-line N-of-1 treatments in the I-PREDICT treatment-naïve study.
Jason K Sicklick, Shumei Kato, Ryosuke Okamura, Hitendra Patel, Mina Nikanjam, Paul T Fanta, Michael E Hahn, Pradip De, Casey Williams, Jessica Guido,[...]. Genome Med 2021
11
66

Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial.
Thomas Powles, Tibor Csőszi, Mustafa Özgüroğlu, Nobuaki Matsubara, Lajos Géczi, Susanna Y-S Cheng, Yves Fradet, Stephane Oudard, Christof Vulsteke, Rafael Morales Barrera,[...]. Lancet Oncol 2021
118
33

Publisher Correction: Clinical efficacy and biomarker analysis of neoadjuvant atezolizumab in operable urothelial carcinoma in the ABACUS trial.
Thomas Powles, Mark Kockx, Alejo Rodriguez-Vida, Ignacio Duran, Simon J Crabb, Michiel S Van Der Heijden, Bernadett Szabados, Albert Font Pous, Gwenaelle Gravis, Urbano Anido Herranz,[...]. Nat Med 2020
1
100

Enfortumab Vedotin Antibody-Drug Conjugate Targeting Nectin-4 Is a Highly Potent Therapeutic Agent in Multiple Preclinical Cancer Models.
Pia M Challita-Eid, Daulet Satpayev, Peng Yang, Zili An, Karen Morrison, Yuriy Shostak, Arthur Raitano, Rossana Nadell, Wendy Liu, Dawn Ratay Lortie,[...]. Cancer Res 2016
206
33

FGFR alterations in urothelial carcinoma: Picking the right target.
Paul Hubert, Zohair Selmani, Yohann Loriot, Antoine Thiery-Vuillemin. Bull Cancer 2021
1
100

Trastuzumab, paclitaxel, carboplatin, and gemcitabine in advanced human epidermal growth factor receptor-2/neu-positive urothelial carcinoma: results of a multicenter phase II National Cancer Institute trial.
Maha H A Hussain, Gary R MacVicar, Daniel P Petrylak, Rodney L Dunn, Ulka Vaishampayan, Primo N Lara, Gurkamal S Chatta, David M Nanus, L Michael Glode, Donald L Trump,[...]. J Clin Oncol 2007
268
33

Targeted therapies for advanced bladder cancer: new strategies with FGFR inhibitors.
Chiara Casadei, Nazli Dizman, Giuseppe Schepisi, Maria Concetta Cursano, Umberto Basso, Daniele Santini, Sumanta K Pal, Ugo De Giorgi. Ther Adv Med Oncol 2019
57
33

Molecular classification of urothelial carcinoma: global mRNA classification versus tumour-cell phenotype classification.
Gottfrid Sjödahl, Pontus Eriksson, Fredrik Liedberg, Mattias Höglund. J Pathol 2017
191
33

Fibroblast Growth Factor Receptors (FGFRs) and Noncanonical Partners in Cancer Signaling.
Harriet R Ferguson, Michael P Smith, Chiara Francavilla. Cells 2021
18
33


Hyperprogressive disease: recognizing a novel pattern to improve patient management.
Stéphane Champiat, Roberto Ferrara, Christophe Massard, Benjamin Besse, Aurélien Marabelle, Jean-Charles Soria, Charles Ferté. Nat Rev Clin Oncol 2018
224
33

Neoadjuvant PD-L1 plus CTLA-4 blockade in patients with cisplatin-ineligible operable high-risk urothelial carcinoma.
Jianjun Gao, Neema Navai, Omar Alhalabi, Arlene Siefker-Radtke, Matthew T Campbell, Rebecca Slack Tidwell, Charles C Guo, Ashish M Kamat, Surena F Matin, John C Araujo,[...]. Nat Med 2020
96
33

Bladder Cancer, Version 3.2020, NCCN Clinical Practice Guidelines in Oncology.
Thomas W Flaig, Philippe E Spiess, Neeraj Agarwal, Rick Bangs, Stephen A Boorjian, Mark K Buyyounouski, Sam Chang, Tracy M Downs, Jason A Efstathiou, Terence Friedlander,[...]. J Natl Compr Canc Netw 2020
225
33

Preoperative ipilimumab plus nivolumab in locoregionally advanced urothelial cancer: the NABUCCO trial.
Nick van Dijk, Alberto Gil-Jimenez, Karina Silina, Kees Hendricksen, Laura A Smit, Jeantine M de Feijter, Maurits L van Montfoort, Charlotte van Rooijen, Dennis Peters, Annegien Broeks,[...]. Nat Med 2020
120
33


The mTOR pathway affects proliferation and chemosensitivity of urothelial carcinoma cells and is upregulated in a subset of human bladder cancers.
Igor Makhlin, Jiaru Zhang, Christopher J Long, Karthik Devarajan, Yan Zhou, Andres J Klein-Szanto, Min Huang, Jonathan Chernoff, Stephen A Boorjian. BJU Int 2011
30
33

Everolimus and pazopanib (E/P) benefit genomically selected patients with metastatic urothelial carcinoma.
Joaquim Bellmunt, Aly-Khan A Lalani, Sussana Jacobus, Stephanie A Wankowicz, Laura Polacek, David Y Takeda, Lauren C Harshman, Nikhil Wagle, Irene Moreno, Kevin Lundgren,[...]. Br J Cancer 2018
18
33

Impact of HER2 assessment by CISH in urothelial carcinoma: A retrospective single-center experience.
Alessandro Rizzo, Veronica Mollica, Francesca Giunchi, Filippo Gustavo Dall'Olio, Matteo Rosellini, Andrea Marchetti, Tania Franceschini, Riccardo Schiavina, Eugenio Brunocilla, Michelangelo Fiorentino,[...]. Pathol Res Pract 2021
1
100

Adjuvant Nivolumab versus Placebo in Muscle-Invasive Urothelial Carcinoma.
Dean F Bajorin, J Alfred Witjes, Jürgen E Gschwend, Michael Schenker, Begoña P Valderrama, Yoshihiko Tomita, Aristotelis Bamias, Thierry Lebret, Shahrokh F Shariat, Se Hoon Park,[...]. N Engl J Med 2021
145
33

HER2 expression status in diverse cancers: review of results from 37,992 patients.
Min Yan, Maria Schwaederle, David Arguello, Sherri Z Millis, Zoran Gatalica, Razelle Kurzrock. Cancer Metastasis Rev 2015
205
33

Multicentre randomised phase II trial of gemcitabine+platinum, with or without trastuzumab, in advanced or metastatic urothelial carcinoma overexpressing Her2.
Stéphane Oudard, Stéphane Culine, Yann Vano, François Goldwasser, Christine Théodore, Thierry Nguyen, Eric Voog, Eugeniu Banu, Annick Vieillefond, Franck Priou,[...]. Eur J Cancer 2015
82
33

Efficacy of BGJ398, a Fibroblast Growth Factor Receptor 1-3 Inhibitor, in Patients with Previously Treated Advanced Urothelial Carcinoma with FGFR3 Alterations.
Sumanta K Pal, Jonathan E Rosenberg, Jean H Hoffman-Censits, Raanan Berger, David I Quinn, Matthew D Galsky, Juergen Wolf, Christian Dittrich, Bhumsuk Keam, Jean-Pierre Delord,[...]. Cancer Discov 2018
155
33

A molecular taxonomy for urothelial carcinoma.
Gottfrid Sjödahl, Martin Lauss, Kristina Lövgren, Gunilla Chebil, Sigurdur Gudjonsson, Srinivas Veerla, Oliver Patschan, Mattias Aine, Mårten Fernö, Markus Ringnér,[...]. Clin Cancer Res 2012
540
33

Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial.
Jonathan E Rosenberg, Jean Hoffman-Censits, Tom Powles, Michiel S van der Heijden, Arjun V Balar, Andrea Necchi, Nancy Dawson, Peter H O'Donnell, Ani Balmanoukian, Yohann Loriot,[...]. Lancet 2016
33

Enfortumab Vedotin in Previously Treated Advanced Urothelial Carcinoma.
Thomas Powles, Jonathan E Rosenberg, Guru P Sonpavde, Yohann Loriot, Ignacio Durán, Jae-Lyun Lee, Nobuaki Matsubara, Christof Vulsteke, Daniel Castellano, Chunzhang Wu,[...]. N Engl J Med 2021
179
33

Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial.
Thomas Powles, Ignacio Durán, Michiel S van der Heijden, Yohann Loriot, Nicholas J Vogelzang, Ugo De Giorgi, Stéphane Oudard, Margitta M Retz, Daniel Castellano, Aristotelis Bamias,[...]. Lancet 2018
789
33

Metastatic Urothelial Cancer: a rapidly changing treatment landscape.
Carlos Stecca, Osama Abdeljalil, Srikala S Sridhar. Ther Adv Med Oncol 2021
8
33

Comprehensive Molecular Characterization of Muscle-Invasive Bladder Cancer.
A Gordon Robertson, Jaegil Kim, Hikmat Al-Ahmadie, Joaquim Bellmunt, Guangwu Guo, Andrew D Cherniack, Toshinori Hinoue, Peter W Laird, Katherine A Hoadley, Rehan Akbani,[...]. Cell 2017
33


Dovitinib: rationale, preclinical and early clinical data in urothelial carcinoma of the bladder.
Clarisse R Mazzola, Khurram M Siddiqui, Michele Billia, Joseph Chin. Expert Opin Investig Drugs 2014
11
33

The evolving genomic landscape of urothelial carcinoma.
Alexander P Glaser, Damiano Fantini, Ali Shilatifard, Edward M Schaeffer, Joshua J Meeks. Nat Rev Urol 2017
67
33

Whole-exome sequencing of muscle-invasive bladder cancer identifies recurrent mutations of UNC5C and prognostic importance of DNA repair gene mutations on survival.
Kai Lee Yap, Kazuma Kiyotani, Kenji Tamura, Tatjana Antic, Miran Jang, Magdeline Montoya, Alexa Campanile, Poh Yin Yew, Cory Ganshert, Tomoaki Fujioka,[...]. Clin Cancer Res 2014
58
33

Adjuvant immunotherapy in muscle-invasive urothelial carcinoma.
Alessandro Rizzo, Veronica Mollica, Francesco Massari. Lancet Oncol 2021
2
50

mTOR signaling in growth control and disease.
Mathieu Laplante, David M Sabatini. Cell 2012
33

HER2 overexpression in muscle-invasive urothelial carcinoma of the bladder: prognostic implications.
Stefan Krüger, Georg Weitsch, Hartwig Büttner, Arne Matthiensen, Torsten Böhmer, Tim Marquardt, Friedhelm Sayk, Alfred C Feller, Andreas Böhle. Int J Cancer 2002
130
33

Efficacy and safety of rucaparib in previously treated, locally advanced or metastatic urothelial carcinoma from a phase 2, open-label trial (ATLAS).
P Grivas, Y Loriot, R Morales-Barrera, M Y Teo, Y Zakharia, S Feyerabend, N J Vogelzang, E Grande, N Adra, A Alva,[...]. BMC Cancer 2021
15
33


The dilemma of neoadjuvant and adjuvant therapy in urothelial carcinoma: will immunotherapy solve the problem?
Giacomo Nuvola, Alessandro Rizzo, Veronica Mollica, Francesco Massari. Immunotherapy 2022
1
100

Fibroblast growth factor receptors in cancer: genetic alterations, diagnostics, therapeutic targets and mechanisms of resistance.
Melanie A Krook, Julie W Reeser, Gabrielle Ernst, Hannah Barker, Max Wilberding, Gary Li, Hui-Zi Chen, Sameek Roychowdhury. Br J Cancer 2021
55
33


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.